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The aim of this thesis is to evaluate the impact of selected rheumatic diseases on health and social 
insurance, and to investigate the severity and cost of individual items and the distribution of costs among 
specific subgroups of patients according to type of therapy or disease severity.  
 
The methodology used was a Cost-Of-Illness analysis from the societal perspective. Data on treatment, 
reduction of labour productivity and level of disability were collected through questionnaires (between 
members of patient organizations or doctors). Indirect costs for all diagnoses were calculated by using the 
Friction Cost Approach and due to the same methodology can be compared.  
 
The dissertation is presenting cost analysis of ankylosing spondylitis (AS), psoriatic arthritis (PsA), psoriasis 
(Ps) and rheumatoid arthritis (RA). Study cohorts included 1 008 and 509 patients with AS, 256 patients with 
Ps and 88 patients simultaneously with PsA and 261 patients with RA. Total costs ranged from 94 492 CZK 
(Ps) to 228 623 CZK (RA) per patient for the disease and the direct costs ranged from 37 % (AS) to 81 % 
(RA). The lowest percentage of the cost of lost productivity to total costs was recorded in the diagnosis of RA 
(18,9 %), Ps (22,7 %) and PsA 31,6%) were highest in AS (55,9% at Beda II and 62,8 % by Beda II). In RA 
patients, we found that the costs correlate with disease severity. In a cohort of patients with PS and / or PsA 
presence increases the cost of the disease.  
 
Our present results can serve as a basis for further pharmacoeconomic analysis, e.g. cost-effectiveness 
analysis or can serve as a support for decision-makers in the health sector. 
